NCT03035396

Brief Summary

The primary objective of this study is device feasibility of the Diassess Influenza A and B Test

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
567

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 29, 2016

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

January 20, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 30, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

February 6, 2018

Status Verified

February 1, 2018

Enrollment Period

4 months

First QC Date

January 20, 2017

Last Update Submit

February 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Diassess test measurement agreement with Polymerase Chain Reaction (PCR)

    One (1) patient visit which is a time frame of one (1) hour

Study Arms (1)

Diassess Influenza A and B Test

EXPERIMENTAL
Device: Diassess Influenza A and B Test

Interventions

Diassess Influenza A and B Test

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Subject currently has a fever (≥37.8°C/100°F), or self-reports having had or is currently treating a fever ≥37.8°C/100°F with onset within the previous 72 hrs
  • Subject has at least one additional flu-like symptom including fever or feeling feverish/chills, runny or stuffy nose, muscle or body aches, fatigue (very tired), sore throat, headaches, or cough

You may not qualify if:

  • Subject received nasal vaccine (e.g. FluMist) within the past 10 days
  • Subject has been taking or took any antivirals for influenza in the past 30 days
  • Subject enrolled in any drug trials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Health Care Center

Syracuse, New York, 13202, United States

Location

MeSH Terms

Conditions

Influenza, Human

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract Diseases

Study Officials

  • Carol Chen, PhD

    Diassess Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2017

First Posted

January 30, 2017

Study Start

December 29, 2016

Primary Completion

May 1, 2017

Study Completion

May 1, 2017

Last Updated

February 6, 2018

Record last verified: 2018-02

Locations